Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Director | January 10, 2019 | January 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date January 10, 2019 · Filed January 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 2,654,871 |
Reported balance
After 2019-01-10 transaction · row 1
1 source rowRow 1 · 2019-01-10 · Grant · Acquired 12,500 · Balance 2,654,871 F1: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.66 · Expires 2029-01-10 | Direct | 75,000 |
Reported balance
After 2019-01-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-10 · Grant · Acquired 75,000 · Balance 75,000 F3: These options were granted on 01/10/2019. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2028-02-16 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2019-01-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 40,000 F4: These options were granted on 2/16/2018. These options vest in full on the first anniversary of the date of grant, subject to continued service on the board. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2027-08-03 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2019-01-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 75,000 F5: These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019. |
| Common StockSEC Table I · non-derivative | IndirectLandmark Foundation | 14,000 |
Reported balance
Holding disclosure · report date 2019-01-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,000 F2: Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees. |
| Series C-3 Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 500,000 |
Reported balance
Holding disclosure · report date 2019-01-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 500,000 F6: The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual. |
| Warrant (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2020-01-01 | Direct | 250,000 |
Reported balance
Holding disclosure · report date 2019-01-10 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 250,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board.
F2: Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
F3: These options were granted on 01/10/2019. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.
F4: These options were granted on 2/16/2018. These options vest in full on the first anniversary of the date of grant, subject to continued service on the board.
F5: These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019.
F6: The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2019 Filed Jan 11, 2019 16:13 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 75,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000380 · section16.xml · derivative · entry 3 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-10 F3 · derivative.exercise_date: These options were granted on 01/10/2019. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 16:13 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantRestricted Stock Units | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-19-000380 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,654,871 F1 · price: These shares consist of restricted stock units granted on 01/10/2019. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 17:07 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionSeries B Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · derivative · entry 4 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F2 · derivative.exercise_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F2 · derivative.expiration_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 17:07 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 468,750 | $2.24 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · nonDerivative · entry 2 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,632,371 Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 17:07 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 1,000,000 | $1.05 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,101,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2018 Filed Nov 30, 2018 16:12 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionSeries B Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · derivative · entry 4 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F3 · derivative.exercise_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. F3 · derivative.expiration_date: The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date. Read SEC document |
| October 12, 2018 Filed Nov 30, 2018 16:12 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 468,750 | $2.24 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · nonDerivative · entry 2 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,642,371 F1 · balance_after: This amendment is being filed solely to correct the reporting person's holdings to reflect an ownership correction to a report filed on 2/20/2018 and amended the same date as this amended report. Read SEC document |
| October 12, 2018 Filed Nov 30, 2018 16:12 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 1,000,000 | $1.05 | $1,050,000.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,111,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amendment is being filed solely to correct the reporting person's holdings to reflect an ownership correction to a report filed on 2/20/2018 and amended the same date as this amended report. Read SEC document |
| September 10, 2018 Filed Oct 16, 2018 17:07 UTC | CorMedix Inc. CRMD · Entity 5280 | OtherSeries A Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001654954-18-011239 · section16.xml · derivative · entry 5 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed F3 · security: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant was exercisable for a period of thirteen months from the Initial Exercise Date and expired unexercised on September 10, 2018.. F3 · derivative.exercise_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant was exercisable for a period of thirteen months from the Initial Exercise Date and expired unexercised on September 10, 2018.. F3 · derivative.expiration_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant was exercisable for a period of thirteen months from the Initial Exercise Date and expired unexercised on September 10, 2018.. Read SEC document |
| September 10, 2018 Filed Nov 30, 2018 16:12 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | OtherSeries A Common Stock Warrant · Derivative | 1,000,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001654954-18-013410 · section16.xml · derivative · entry 5 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 1,000,000 shares Expires not disclosed F4 · security: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date. F4 · derivative.exercise_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date. F4 · derivative.expiration_date: The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 16:03 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-001718 · section16.xml · derivative · entry 4 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vests in full on the first anniversary of the date of grant, subject to continued service on the board. F3 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vests in full on the first anniversary of the date of grant, subject to continued service on the board. F3 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vests in full on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 16:03 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 40,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001654954-18-001718 · section16.xml · derivative · entry 3 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-02-16 F2 · derivative.exercise_date: These options vest in full on the first anniversary of the date of grant, subject to continued service on the board. Read SEC document |
| February 16, 2018 Filed Nov 30, 2018 16:19 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-18-013415 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,111,121 F1 · price: These shares consist of restricted stock units granted on 2/16/2018. These restricted stock units will vest monthly with full vesting on the first anniversary of the date of grant, subject to continued service on the board. This amendment reports the restricted stock units in Table I rather than Table II as originally reported. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:12 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock, $0.001 par value per share | 52,083 | $0.48 | $24,999.84 |
DisclosureSEC source: 0001654954-17-011653 · section16.xml · nonDerivative · entry 1 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,101,121 F1 · date: Purchase was contracted on November 17, 2017, but not closed until December 12, 2017. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 16:31 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001654954-17-007011 · section16.xml · derivative · entry 3 Gelbfish Gary A. · CIK 0001488011 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, $0.001 par value per share · 75,000 shares Expires 2027-08-03 F2 · derivative.exercise_date: These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.